Halozyme Thrp Stock Price, News & Analysis

Halozyme Therapeutics, Inc. (NASDAQ: HALO) plans to redeem all outstanding 1.25% convertible senior notes due 2024 on March 17, 2023. Holders can convert their notes at a rate of 42.0331 shares per $1,000 principal amount, equating to a conversion price of approximately $23.79 per share. Non-converted notes will be redeemed at 100% of their principal plus accrued interest. This action is part of the company's strategy to manage its debt effectively.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced robust financial guidance for 2023, projecting total revenues of $815 to $845 million, representing over 20% growth versus 2022. Recurring revenues from royalties are expected to exceed $445 million, marking a similar growth rate. The EBITDA is projected to rise by over 30%, reaching between $415 and $440 million. Non-GAAP diluted EPS guidance ranges from $2.50 to $2.65. The company anticipates two new commercial launches and significant growth in its ENHANZE pipeline.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will have its president and CEO, Dr. Helen Torley, present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT. The event will be accessible via a live audio webcast on the company's Investor Relations page, with replays available for 30 days. Halozyme is known for its innovative ENHANZE® technology, facilitating drug delivery for better patient outcomes and has impacted over 600,000 patients globally. The company also develops advanced drug-device combination products to enhance patient comfort and adherence.

Halozyme Therapeutics (NASDAQ: HALO) has announced participation in several upcoming investor conferences. Management, led by Dr. Helen Torley, will present at the J.P. Morgan Equity Opportunities Forum on November 15, 2022, in Miami, FL, and at the Piper Sandler Health Conference on November 30, 2022, in New York, NY, followed by the Evercore IS HealthCONx Conference on December 1, 2022, in a virtual format. Live webcasts of the events will be available on Halozyme's Investor Relations section.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported third quarter revenue of $209 million, up 80% year-over-year, with GAAP diluted EPS of $0.44 and non-GAAP diluted EPS of $0.74. Royalty revenue rose 70% year-over-year to $99.6 million. The company reiterated its 2022 revenue guidance of $655 million to $685 million, anticipating 48%-55% growth compared to 2021. Key advancements include regulatory submissions for ENHANZE® products. Cash and equivalents stood at $265.6 million as of September 30, 2022.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its third quarter 2022 financial and operating results on November 8, 2022, after the market closes. A conference call will follow at 4:30 p.m. ET to discuss these results. Interested parties can register for the call here, and a live webcast will also be available on Halozyme's investor relations site. Halozyme, known for its ENHANZE® technology, aims to enhance patient experiences through innovative biopharmaceutical solutions.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced Dr. Helen Torley's participation at the 2022 Wells Fargo Healthcare Conference from September 7-9, 2022, in Boston, MA. Dr. Torley will present on September 8 at 5:35 a.m. PT / 8:35 a.m. ET, alongside hosting investor meetings. A live audio webcast of the presentation will be available on the Company’s Investor Relations section, with replays accessible for 90 days post-conference. Halozyme is renowned for its ENHANZE® technology, enhancing drug delivery and improving patient experiences.

Halozyme Therapeutics (NASDAQ: HALO) announced the pricing of a $625 million offering of convertible senior notes due 2028, upsized from an initial $500 million. The notes will bear an interest rate of 1.00% and are convertible at a rate of 17.8517 shares per $1,000 principal amount, equating to an initial conversion price of $56.02. Proceeds of approximately $608.7 million will be used for capped call transactions, repurchasing existing convertible notes, and share repurchases, among other corporate purposes, set to close on August 18, 2022.

Halozyme Therapeutics plans a $500 million offering of convertible senior notes due 2028, subject to market conditions, with an option for an additional $75 million. The company intends to use proceeds for capped call transactions, repurchasing shares up to $200 million, and repaying a $250 million term loan due 2026. The offering could potentially influence the market price of Halozyme's common stock.